Key Highlights

  • STAAR Surgical (NASDAQ:STAA) was quoted 9.68% higher at USD 29.80 in premarket trading on November 5, 2026, with USD 206.4 million in cash and no debt.
  • Myriad Genetics (NASDAQ:MYGN) was quoted 8.14% higher at USD 6.51 after agreeing to sell its Prenatal Health Business for USD 210 million in cash.
  • Veracyte, Inc. (NASDAQ:VCYT) was quoted 24.79% lower at USD 39.50 after trimming 2026 testing Revenue guidance.
  • Caris Life Sciences (NASDAQ:CAI) was quoted 14.12% lower at USD 28.53 despite 27% revenue growth. Accuray Incorporated (NASDAQ:ARAY) was quoted 19.58% lower at USD 0.1199 before a 1-for-40 reverse split.

Myriad Genetics (NASDAQ:MYGN): Divestiture Overshadows a Wider Loss

Myriad Genetics (NASDAQ:MYGN) reported third-quarter 2026 results in an 8-K dated November 4, 2026, and the shares were quoted 8.14% higher at USD 6.51 in premarket trading on November 5, 2026, per the premarket quote. Revenue was USD 202.7 million, down 1%, and the GAAP net loss widened to USD 43.9 million, or USD 0.46 per share, from USD 27.4 million. Adjusted EBITDA was a loss of USD 5.3 million against a profit of USD 10.3 million. On October 19, 2026 the company agreed to sell its Prenatal Health business to Labcorp for USD 210 million in cash plus inventory value at closing, with completion expected by early 2027. Prenatal Health revenue fell 12% to USD 39.3 million. Cash was USD 107.1 million against long-term Debt of USD 121.1 million. Full-year revenue guidance is USD 780 million to USD 790 million. The sale remains subject to regulatory approvals, so closing is an expectation, not a certainty, and the continuing business will be smaller because Prenatal Health contributes roughly USD 160 million of the 2026 outlook. A premarket move can narrow once Volume arrives.

Veracyte, Inc. (NASDAQ:VCYT): Beat on Profit, Cut to the Testing Range

Veracyte, Inc. (NASDAQ:VCYT) reported third-quarter 2026 results on November 4, 2026, and the shares were quoted 24.79% lower at USD 39.50 in premarket trading on November 5, 2026, per the premarket quote. Revenue rose 15% to USD 151.8 million, led by Decipher Prostate at USD 92.3 million and Afirma at USD 51.5 million, and GAAP Net Income was USD 31.5 million. The apparent catalyst for the selloff is guidance: 2026 testing revenue is now expected at USD 571 million to USD 573 million, down from USD 576 million to USD 582 million, while total revenue guidance moved to USD 590 million to USD 593 million from USD 590 million to USD 596 million. A diagnostics company can beat on volume and profit, yet a lower forward revenue range resets the growth built into the share price. Adjusted EBITDA Margin guidance of more than 26% was unchanged. The board authorized a repurchase of up to USD 100 million over 12 months, and cash was USD 370.5 million. Payer reimbursement and concentration in two main products are risks, and a premarket quote can move once regular trading begins.

Caris Life Sciences (NASDAQ:CAI): Growth Meets a Margin and Cash Reset

Caris Life Sciences (NASDAQ:CAI) reported third quarter 2026 results on November 4, 2026, and the stock was quoted 14.12% lower at USD 28.53 in premarket trading on November 5, 2026, per the premarket quote. Revenue was USD 275.4 million, up 27%, with about 61,500 clinical cases, up 21%, and full-year guidance was raised to USD 1.04 billion to USD 1.05 billion. The pressure likely stems from profitability and cash: gross margin was 66% against 68%, adjusted EBITDA fell to USD 44.4 million from USD 51.2 million and free Cash Flow was negative USD 39.7 million. Negative free cash flow can reflect Working Capital timing, because laboratories bill payers after testing and collect later, but investors will want to see it reverse. Net income was USD 15.3 million, or USD 0.05 per share. Cash and restricted cash were USD 665.3 million against net long-term indebtedness of USD 393.2 million. Comparison with analyst consensus was not verified, so the size of any miss is unconfirmed. Next checks are clinical case growth against the 20% volume target and gross margin direction.

STAAR Surgical (NASDAQ:STAA): Distorted Comparison, Cash and No Debt

STAAR Surgical (NASDAQ:STAA) reported third quarter 2026 results on November 4, 2026 for the quarter ended October 2, 2026, and the shares were quoted 9.68% higher at USD 29.80 in premarket trading on November 5, 2026, per the premarket quote. Net sales were USD 83.4 million, down 12%, but the comparison is distorted: the prior-year quarter included USD 25.9 million of previously deferred China sales, and excluding that amount sales grew 21%. GAAP net income was USD 5.6 million, or USD 0.11 per diluted share. Gross margin was 70.9% against 82.2%. Cash, equivalents and investments were USD 206.4 million with no debt, and a USD 50 million share repurchase program was authorized in September 2026. The company gave qualitative rather than numeric guidance, so there is no hard full-year target to measure against. China seasonality is expected to moderate fourth quarter revenue. Management cited a 5.8% fall in laser vision correction procedures in 2026, a reminder that refractive Demand is cyclical. These figures come from a single republished copy of the company release.

Accuray Incorporated (NASDAQ:ARAY): Reverse Split and a Debt-for-Equity Rescue

Accuray Incorporated (NASDAQ:ARAY) was quoted 19.58% lower at USD 0.1199 in premarket trading on November 5, 2026, per the premarket quote, after a release and Form 8-K dated November 4, 2026 announcing a 1-for-40 reverse split effective at 12:02 a.m. ET on November 9, 2026. About 120.2 million shares will become roughly 3.0 million, and authorized common shares fall from 400,000,000 to 10,000,000. A reverse split exchanges many old shares for one new share, raising the quoted price without changing a holder's percentage ownership. Nasdaq granted until February 1, 2027 to regain the USD 1.00 minimum bid price. The financing with TCW Asset Management includes an exchange of USD 40 million of term Loan debt for convertible preferred stock, a USD 15 million Equity Investment and a delayed draw term loan of up to USD 5 million. That reduces Leverage but adds potential dilution for common holders. No latest revenue or Earnings figures were verified. With the shares well under USD 1.00, a small number of trades can move the price, spreads can be wide and quoted moves can reverse.

Where Things Stand

Diagnostics and MedTech shares are reacting less to growth than to guidance, margins and Balance Sheet events, so the evidence favors reading the fine print. Myriad Genetics (NASDAQ:MYGN) gains on a divestiture despite a wider loss. Veracyte, Inc. (NASDAQ:VCYT) falls because its testing range was trimmed. Caris Life Sciences (NASDAQ:CAI) falls on margin and cash flow despite raised revenue guidance. STAAR Surgical (NASDAQ:STAA) gains on an adjusted growth rate of 21% and cash. Accuray Incorporated (NASDAQ:ARAY) is a nano-cap reverse split situation. Premarket quotes are snapshots.